Premier Alternatives

Bold Therapeutics

Vancouver, Canada · Founded 2018 · Privately Held (backing)

Developer of novel metallotherapeutics metal-based small molecules designed for the treatment of cancer. Bold Therapeutics is based in Vancouver, Canada and was founded in 2018. Its last known valuation is $140 million. It has raised $25 million across 1 recorded round; the latest was a $5.5 million early-stage round in Jul 2018.

Last price · $/share
—
Implied valuation
$140.0M
Total raised
$25.0M
Last round
Early Stage VC
Jul 2018

Bold Therapeutics key facts

  • Developer of novel metallotherapeutics metal-based small molecules designed for the treatment of cancer.
  • Bold Therapeutics’s last known valuation is $140.0M.
  • It has raised $25.0M across 1 recorded rounds; the latest was Early Stage VC ($5.5M) in Jul 2018.
  • Notable investors include Life Sciences BC, Gaston Capital, National Research Council Canada, Tampa Bay Technology Incubator.
  • Bold Therapeutics has filed 1 Form D with the SEC, most recently Feb 2021 ($5.5M sold to 48 investors).
  • Status: Privately Held (backing).
Free account
More of Bold Therapeutics with a free account
  • ·Watch Bold Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Bold Therapeutics funding rounds

1 rounds
Jul 2018Early Stage VC$5.5MSEC filing▮
Full funding history →

Bold Therapeutics valuation

Bold Therapeutics's last known valuation is $140 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Bold Therapeutics raised?

Bold Therapeutics has raised $25 million in total; 1 of its rounds is on record. The largest on record was a $5.5 million early-stage round in Jul 2018.

Bold Therapeutics has filed 1 Form D with the SEC, most recently in Feb 2021 ($5.5 million sold to 48 investors).

Bold Therapeutics investors

4 investors are on record for Bold Therapeutics, including Life Sciences BC, Gaston Capital, National Research Council Canada and Tampa Bay Technology Incubator. The early-stage round in Jul 2018 drew 48 investors.

About Bold Therapeutics

Developer of novel metallotherapeutics metal-based small molecules designed for the treatment of cancer. The company's lead asset, a ruthenium-based small molecule therapeutic, exhibits significant synergy with the activity of a range of other anti-cancer therapies by disabling critical pathways that support survival and proliferation, enabling doctors to reduce the ability of cancer cells to develop resistance.

Sector
Healthcare
HQ
Vancouver, Canada
Founded
2018
Employees
20
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$140.0M

Bold Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.